Who Paid My Doc
Waseem Ahmad
San Francisco, CA Medical Doctor
NPI 1649633991 CMS profile 7230229
1701 Divisadero St Ste 120, Ste 120, San Francisco, CA 94115
General payments
$363
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Waseem Ahmad of San Francisco, CA is reported in the CMS Open Payments database as having received $363 across 8 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $50 | 2 | |
| 2022 | General | $157 | 3 | |
| 2021 | General | $139 | 2 | |
| 2019 | General | $18 | 1 |
Beside peers
- Waseem Ahmad
- California median
- Middle half of California
- National median
In program year 2025, general payments to Waseem Ahmad were reported at $0. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.
Show as a table
| Year | Waseem Ahmad | California median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $18 | $161 | $50–$652 | $163 |
| 2020 | $0 | $114 | $34–$392 | $114 |
| 2021 | $139 | $137 | $41–$509 | $132 |
| 2022 | $157 | $152 | $48–$573 | $149 |
| 2023 | $50 | $162 | $50–$581 | $160 |
| 2024 | $0 | $162 | $52–$583 | $164 |
| 2025 | $0 | $172 | $54–$610 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
76
Drug cost
$28,085
Branded share of claims
15.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xifaxan Rifaximin | Brand | 12 | $27,193 | |
| Famotidine | Generic | 23 | $401 | |
| Omeprazole | Generic | 24 | $324 | |
| Mirtazapine | Generic | 17 | $167 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 37 billing codesPaid by Medicare
$71,074
Medicare patients
349
Services billed
679
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 60% | |
| Arthritis | 40% | |
| Depression | 28% | |
| Diabetes | 23% | |
| Ischemic heart disease | 22% | |
| Chronic kidney disease | 21% | |
| Cancer | 21% | |
| Osteoporosis | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
8 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.